Our previous studies revealed a defect in B cell tolerance as evidenced by the spontaneous development of autoantibodies in *Siae* mutant mice on a C57BL/6 background[@R1]. Given this phenotype we sought to ask if this enzyme was linked to autoimmunity in human subjects. Although genome wide association studies had not revealed altered frequencies of common variants of *SIAE* in patients with autoimmunity, the possibility that loss-of-function rare variants of this gene might be enriched in patients with autoimmune disorders was addressed by complete re-sequencing of all the exons of *SIAE* in patients with autoimmunity and in healthy controls.

In the first phase of our studies we completely re-sequenced the *SIAE* gene from 188 subjects with autoimmunity and 190 healthy controls as described below. Initially we analyzed 19 subjects from Massachusetts General Hospital (MGH) selected only on the basis of their having high ANA titers. 13 of these 19 subjects had defined autoimmune disorders and were included in our studies. In this initial set of 13 Caucasian subjects, unique non-synonymous changes were observed in one subject with Crohn's disease and in one subject with rheumatoid arthritis (RA). As a result of these preliminary observations, we next analyzed 76 Caucasian subjects with RA from the NARAC (North American Rheumatoid Arthritis Consortium) collection, and 89 subjects with inflammatory bowel disease (IBD) from MGH, making an initial total of 188 autoimmune subjects. The only criterion used in selection was ethnicity. The control DNAs in this initial phase were obtained from 190 healthy volunteers at MGH primarily of European ancestry. Re-sequencing of all 10 exons of *SIAE* revealed the existence of point substitutions in *SIAE* in both patients and controls. A number of known SNPs were identified as expected ([Supplementary Table I](#SD1){ref-type="supplementary-material"}). A total of 19 out of 923 autoimmune subjects presented with one of 14 previously unidentified non-synonymous SNPs in the *SIAE* gene, while 8 other autoimmune subjects had a homozygous polymorphism resulting in a valine replacing methionine at position 89 ([Table I](#T1){ref-type="table"}). Among control subjects, 17/648 presented with one of 8 non-synonymous SNPs in the *SIAE* gene. No controls presented with the homozygous 89V/89V polymorphic form of SIAE ([Table I](#T1){ref-type="table"}). Functional analyses were performed on each SIAE variant as described below.

Since the initial analyses revealed a marked enrichment of loss-of-function *SIAE* variants in autoimmune subjects as compared with controls, a larger number of autoimmune subjects and controls were analyzed. Power calculations revealed that a sample size of 550 cases and 550 controls would be required to obtain a power of at least 0.80 (see power table and calculations in [Supplementary Notes](#SD1){ref-type="supplementary-material"}). Autoimmune subjects in this second phase included more subjects with RA from NARAC, subjects from the MADGC (Multiple Autoimmune Disease Genetics Consortium) collection with systemic lupus erythematosus (SLE) and juvenile idiopathic arthritis (JIA), and subjects from MGH with IBD and rheumatic disorders including SLE, RA, mixed connective tissue disorder (MCTD) and Sjogren's syndrome (SjS). We also included subjects with multiple sclerosis (MS) from a collection at the Brigham and Womens' Hospital, and subjects with Type 1 diabetes (T1D) from the EDIC (Epidemiology of Diabetes Intervention and Complication study) collection of the NIDDK (National Institute of Diabetes, Digestive and Kidney Diseases). Additional healthy control DNAs, primarily from subjects of European ancestry, were obtained from the MGH Cancer Center, the Feinstein Institute and the phenogenetic collection at Brigham and Womens' Hospital.

In order to determine whether variants were functional or defective, we recreated the changes corresponding to all the coding *SIAE* variants that we had discovered in patients and controls into a C-terminal FLAG-tagged human *SIAE* cDNA cloned from MDA-MB 231 cells. Each cDNA was transfected into 293T cells, and lysates and supernatants were each divided into two equal aliquots. SIAE was immunoprecipitated with anti-FLAG antibodies, and one aliquot was saved for a quantitative Western blot assay while the other was utilized in an esterase assay using a fluorogenic substrate, 4-methylumbelliferyl acetate. Quantitative Western blotting was performed using a near infrared-dye labeled second antibody and detected using the Li-Cor Odyssey system. Each cDNA was transfected three or more times and the entire assay performed on at least three occasions for each cDNA.

As described in [Table I](#T1){ref-type="table"} we have now identified 27/923 autoimmune subjects with either rare heterozygous non-synonymous substitutions in *SIAE* that do not represent known SNPs or a specific defective homozygous polymorphism. In 24 of these patients the *SIAE* variants were found to be functionally defective either because of a defect in catalytic activity to below 50% of wild type or because of a profound defect in secretion (in the absence of a catalytic defect). A group of missense variants that are severely catalytically defective include c.935C\>T, c.587G\>T, c.926A\>C, c.634G\>A, c.1435C\>T, c.1178G\>A, and c.688C\>T and encode T312M SIAE, C196F SIAE, Q309P SIAE, G212R SIAE, R479C SIAE, R393H SIAE, and R230W SIAE. The analysis of these severely catalytically defective variants by transfection, immunoprecipitation, enzyme assays and immunoblot assays are shown in [Fig. 1](#F1){ref-type="fig"} and [Supplementary Fig. 3](#SD1){ref-type="supplementary-material"}. These variants are also very poorly secreted presumably because they are grossly misfolded proteins that fail to egress the endoplasmic reticulum.

More modest, but reproducible catalytic defects were seen in the c.1046A\>G variant that encodes Y349C SIAE, and this variant also exhibits reduced secretion (see [Fig. 1](#F1){ref-type="fig"}, bottom panels). The c.1211T\>C variant encodes F404S SIAE that also appears to exhibit a less severe catalytic defect (but nevertheless below the 50% cutoff set), similar to that seen in Y349C SIAE ([Fig. 1](#F1){ref-type="fig"}). F404S SIAE was found in four autoimmune patients including two blood relatives, one with SLE and the other with juvenile idiopathic arthritis. The c.796T\>G variant found in one subject with Type I diabetes encodes C266G SIAE that is also defective ([Fig. 1](#F1){ref-type="fig"}).

In contrast to the catalytically defective *SIAE* variants seen in patients with autoimmune diseases, with the exception of two variants (R314H and T312M) observed once each in controls ([Table 1](#T1){ref-type="table"}), most of the new *SIAE* variants found in normal subjects did not exhibit reduced catalytic activity, as shown in [Fig 2](#F2){ref-type="fig"}. Interestingly the protein encoded by the 89V polymorphic allele of *SIAE* is catalytically active but is not secreted (see [Fig. 2](#F2){ref-type="fig"}, third set of panels). The 89V polymorphism is quite common in controls in the heterozygous state (9.7%, see [Supplementary Table S1](#SD1){ref-type="supplementary-material"}). In order to more precisely establish that M89V SIAE is secretion defective, 293T cells transfected with wild type and *M89V SIAE* respectively were metabolically labeled with ^35^\[S\] methionine and chased for 10 min, 1h, 2h and 4h. As seen in [Fig. 3b](#F3){ref-type="fig"}, a striking defect in secretion of M89V SIAE was confirmed by this analysis.

Since SIAE exists as a dimer or higher order oligomer ([Supplementary Fig. 2](#SD1){ref-type="supplementary-material"}), we examined whether catalytically dead mutants from patients with autoimmunity on the one hand, and the catalytically active but secretion-defective M89V variant on the other, could function in a dominant interfering manner ([Fig. 3a](#F3){ref-type="fig"}). The K400N allele ([Fig. 1](#F1){ref-type="fig"}) was also tested as a representative catalytically normal SIAE allele. Since the ultimate test of dominant negative function would be to re-create a heterozygous animal with one mutant allele, mutations were recreated in a murine *Siae* cDNA for these studies. As seen in [Fig. 3a](#F3){ref-type="fig"} and [Supplementary Fig.1](#SD1){ref-type="supplementary-material"}, the murine equivalents of the C196F, G212R, Q309P, T312M, Y349C, F404S and R479C variants are capable of dominantly inhibiting wild type SIAE while M89V SIAE and K400N SIAE are not. Based on this finding it was clear that only subjects with homozygous 89V/89V SIAE polymorphisms (as opposed to subjects with heterozygous *M89V* changes) should be considered to be of potential functional relevance for predisposition to autoimmunity.

Strikingly, eight autoimmune subjects (3 with RA, 1 with SLE, 1 with MS, and three with Type I diabetes) are homozygous for c.\[265A\>G\]+\[265A\>G\] polymorphic alleles, which encode 89V/89V SIAE variants, whereas these homozygous genotypes were not observed in a single control. Given the defect in secretion of this variant, we consider it likely that in subjects with homozygous 89V/89V SIAE this esterase is unlikely to be able to effectively access the post-Golgi compartment in which it would normally de-acetylate 9-*O*-acetylated sialoproteins that serve as CD22 ligands. Hardy-Weinberg equilibrium tests for the *M89V* polymorphism showed a deviation from equilibrium for the cases but not for the controls ([Supplementary Tables S2a, 2b, and 2c](#SD1){ref-type="supplementary-material"}). This deviation is statistically significant. Given the overall similarities in the *89V* and *89M* allele frequencies in cases and controls this clearly reflects an enrichment of *89V* homozygotes in autoimmune subjects, strongly supporting a role for this homozygous polymorphism in disease susceptibility.

A number of *SIAE* rare variants were found in patients with autoimmunity that are probably not involved in the genetic predisposition of these subjects to autoimmunity. For example, a c.98A\>G variant encoding N33S SIAE was discovered in a patient with RA and was found to be functionally normal based on the criteria used ([Fig. 1](#F1){ref-type="fig"}, top panels). One patient with Crohn's disease inherited a c.8C\>G variant encoding an A3G change in the signal peptide encoding portion of *SIAE*. The coding region of *SIAE* would be predicted to be intact in this variant though it is theoretically possible that A3G SIAE might not be readily translocated into the ER. We consider it unlikely that A3G SIAE is translocation-defective given the accumulation of SIAE in culture supernatants when *A3G SIAE* is transfected into 293 T cells ([Fig. 1](#F1){ref-type="fig"}, third set of panels). A c.1200G\>T variant that encodes K400N SIAE was discovered in a patient with Crohn's disease initially examined as part of a small subset of patients with high ANA titers. This enzyme is active and is efficiently secreted but always appears in supernatants as a protein doublet ([Fig. 1](#F1){ref-type="fig"}, second set of panels). Lysine 400 is immediately adjacent to a consensus N-glycosylation site, and it may be that a particular N-glycan is added inefficiently in this variant. This variant is however catalytically active and we classify it as a non-defective allele.

An absolute correlation was not found between conservation of amino acid residues of SIAE across species and a requirement for catalytic activity. Of the 11 heterozygous variants that were found to be defective in autoimmune patients only one (C266G) was not conserved between primates and rodents. One of 3 catalytically normal variants identified in autoimmune subjects (N33S SIAE) was also not conserved across species.

In the first phase of this study defective variants were identified in 7/188 autoimmune patients and 0/190 controls. The Odds Ratio could only be calculated as an estimate (Peto Odds Ratio), and this approach yielded an Odds Ratio of 7.71. In the second phase of the study 17/735 autoimmune patients and 2/458 controls inherited defective *SIAE* alleles, and the calculated Odds Ratio was 5.40. In summary, the total number of patients with autoimmune disorders analyzed was 923, with 24/923 inheriting defective *SIAE* alleles, and the total number of ethnically matched controls was 648, with 2/648 controls inheriting defective *SIAE* alleles. The calculated Odds Ratio for all autoimmune disorders was 8.62 with a two-sided p-value of 0.0002.

While care was taken to include only Caucasian non-Jewish subjects in this study, an objective determination of shared ethnicity, a principal components analysis [@R3],[@R4], was conducted on samples with defective *SIAE* alleles and on controls (see [Supplementary Fig.5](#SD1){ref-type="supplementary-material"}). The novel *SIAE* variants that we have observed in subjects with autoimmunity cannot be ascribed to population stratification with respect to controls.

Seven of the 648 controls inherited a non-synonymous rare variant of *SIAE* but only 2/648 inherited defective alleles ([Fig. 2](#F2){ref-type="fig"} and [Table I](#T1){ref-type="table"}). One of the rare variants (c.935C\>T encoding T312M SIAE) found in one of the controls (all 10 exons were sequenced in 648 controls) was identical to a defective variant originally found in a patient with RA and also in a patient with MS. Another variant, (c.941G\>A encoding R314H SIAE), was found in a single control and was also found to be defective ([Fig. 2](#F2){ref-type="fig"}). The remaining rare variants found in controls (c.1340A\>G, c.481C\>A, c.185G\>A, c.1368G\>A, and c.1385A\>G encoding the H447R, Q161K, R62H, M456I and Q462R versions of SIAE respectively) were completely normal as determined by the two assays described (see [Fig. 2](#F2){ref-type="fig"} and [Table I](#T1){ref-type="table"} for a summary). A polymorphic variant c.190G\>A, encoding G64S SIAE, exhibits normal catalytic activity and is readily secreted ([Fig. 2](#F2){ref-type="fig"} and [Table I](#T1){ref-type="table"}), was found in controls, but not found in autoimmune subjects ([Table I](#T1){ref-type="table"} and [Supplementary Table S1](#SD1){ref-type="supplementary-material"}). It might in theory convey protection against disease but a biochemical basis for such a possible protective role is unclear.

All the defective heterozygous *SIAE* alleles in patients that were tested function in a dominant interfering manner in the transfection assay employed. While high Odds Ratios were observed in a number of autoimmune disorders, the results from rheumatoid arthritis subjects (Odds Ratio, 8.3, 2-tailed p= 0.0056) and Type I diabetes patients (Odds Ratio, 7.9, 2-tailed p= 0.0075) were particularly significant. While a dominant negative effect may contribute to disease susceptibility for all tested defective heterozygous variants, we also consider haploinsufficiency to be a possible mechanism for some of the defective variants which might result in the reduction of levels of catalytically active enzyme in B cells below a threshold. This would imply that the W48X alteration found in a patient with type I diabetes ([Table 1](#T1){ref-type="table"}) may be clinically relevant. We plan to examine the effects of haploinsufficiency in mutant mice both on a C57B/6 background as well as in a lupus--prone background.

A number of susceptibility loci for human autoimmune disorders have been uncovered by genome wide association studies, and the relative risks for these associations are generally modest [@R5], [@R6]. A number of recent reports have supported the hypothesis that rare genetic variants can contribute to disease susceptibility. A pioneering study on rare variants in genes that are relevant to lipoprotein synthesis in patients susceptible to cardiovascular disease utilized a predictive algorithm (Polyphen) to determine which variants were probably non-functional[@R7]. Loss-of-function variants in the *Trex* gene, which has a single coding exon, have also been described in patients with SLE[@R8] and a recent re-sequencing study has revealed rare variants in the cytosolic helicase MDA5/IF1H1, which mediates innate immune responses to pathogen encoded RNAs [@R9]. Our results provide important support for a role for rare variation in the predisposition to autoimmune diseases and strikingly illustrate the importance of performing functional assays for the variants being studied. All of the variants identified through re-sequencing are listed in [Supplementary Table S1](#SD1){ref-type="supplementary-material"}. There is clear enrichment of defective coding variants in autoimmune patients as compared to controls ([Table 2](#T2){ref-type="table"}), and it is notable that these variants primarily involved residues that are highly conserved across evolution. While our initial studies strongly support a role for defective *SIAE* rare and polymorphic variants in RA and T1D, a role for these variants in other autoimmune disorders including SLE, MS and IBD appears likely ([Supplementary Table S3](#SD1){ref-type="supplementary-material"}). More extensive studies on these and other autoimmune disorders are called for.

The contribution of B cells to disease, with or without a role for autoantibodies, is recognized in a growing number of diseases including rheumatoid arthritis, multiple sclerosis, and Type1 Diabetes. Mutant *Siae* in rodents results in enhanced B cell activation and a break in B cell tolerance[@R1], but it remains formally possible that SIAE may be required in cell types other than B cells in humans as well as in rodents. One type of inflammatory bowel disease, Crohn's disease, like multiple sclerosis, is generally considered to be etiologically linked to T~H~1 or T~H~17 cells[@R10]. Although B cell depletion can result in marked clinical improvement in patients with multiple sclerosis[@R11], B cells are not generally considered to be of etiopathogenic significance in Crohn's disease; it remains formally possible that autoantigen specific B cells may function as critical antigen presenting cells that secrete cytokines driving helper T cell polarization in certain disease situations. Interestingly, analysis of B cells from a Crohn's disease patient harboring a catalytically defective heterozygous *SIAE* variant (G212R SIAE; see [Table I](#T1){ref-type="table"}) revealed a marked enhancement of cell surface 9-*O*-acetyl sialic acid following BCR activation compared to B cells from a control subject ([Fig. 3c](#F3){ref-type="fig"}). Enhanced 9-*O*-acetylation of sialic acid on B cells was also noted in a patient with Sjogren's syndrome with a heterozygous C196F SIAE variant, and in a patient with lupus with a R393H SIAE variant ([Table I](#T1){ref-type="table"}; [Supplementary Fig.6](#SD1){ref-type="supplementary-material"}). These analyses suggests that a defect in SIAE results in enhanced BCR mediated expression of surface 9-*O*-acetylated sialic acid, while the presence of normal SIAE prevents this enhanced 9-*O*-acetylation event. This phenomenon is being further explored in a range of subjects with autoimmune disorders. Further analyses will be necessary to determine whether there is a role for B cells in disease pathogenesis in a subset of patients with IBD.

SIAE contributes to a signaling mechanism that helps set a threshold for B cell activation, presumably preventing weakly self-reactive B cells from moving towards the T cell zone and consequently being at risk for somatic mutation and for the potential generation of high affinity self-reactive B cells; alternatively SIAE may possibly help maintain tolerance in germinal centers[@R1], [@R2]. The strong association of defective *SIAE* alleles to rheumatoid arthritis and type I diabetes may well represent only the tip of the iceberg for a pathway that includes Lyn, SHP-1, a sialic acid acetyltransferase, SIAE, CD22 and likely other Siglecs expressed in B cells[@R2]. The possibility that SIAE may be of functional relevance in innate immune cells and thus influence disease pathogenesis also deserves exploration.

METHODS {#S1}
=======

Analysis of the sequence of *SIAE* {#S2}
----------------------------------

Each exon of *SIAE* was amplified from genomic DNA from individual subjects and subjected to automated sequencing. Residue numbering was based on ENST00000263593 (Ensembl), corresponding to the Genbank accession number NP_733746. Genomic DNA was extracted from clotted blood specimens from patients with autoimmune disease using a QIAamp DNA blood mini kit (Qiagen, Valencia, CA) according to the manufacturer's instructions. All 10 exons of the human *SIAE* gene were amplified by PCR using intronic primers ([Supplementary Table S4](#SD1){ref-type="supplementary-material"}). Purification of the amplified products, bidirectional automated sequencing and sequence analysis were performed as described earlier[@R13]. All sequence variants were confirmed by sequencing at least two independent PCR amplicons. DNAs from controls were obtained from EBV-immortalized lymphoblastoid cell-lines established from healthy blood donors[@R14]. All blood samples were collected with approval from the MGH/Partners Human Studies Institutional Review Board and from the Institutional Review Board at North Shore Long Island Jewish Health System.

Site directed mutagenesis of human *SIAE* and assays for SIAE catalytic activity and secretion {#S3}
----------------------------------------------------------------------------------------------

A human *SIAE* cDNA was cloned from MDA-MB 231 cells and a full length FLAG-tagged human *SIAE* expression construct (in pcDNA3.1) was generated. This clone was targeted for mutagenesis using PfuTurbo DNA polymerase (Stratagene, CA, USA). Each *SIAE* variant (other than the W48X truncation) was recreated by site directed mutagenesis as a C-terminal FLAG tagged human *SIAE* cDNA in an expression vector Site directed mutagenesis was used to create the S127A variant with a defect in the catalytic site as well as each of the variants listed in [Table I](#T1){ref-type="table"}. The PCR products were digested overnight with DpnI (10 Units; Stratagene) and transformed into TOP10 chemically competent cells (Invitrogen, Carlsbad, CA). Clones containing the mutants were verified by DNA sequencing. All mutant and wild type cDNAs were transfected into HEK 293T cells. Lysates and supernatants were immunoprecipitated with anti-FLAG antibodies and catalytic activity of the immunoprecipitated esterase was assayed by a fluorimetric method[@R15]. Equivalent amounts of each lysate and supernatant were immunoprecipitated for the catalytic assay as well as for quantitation of the FLAG-tagged protein by an immunoblot assay on the LI-COR Odyssey, using a mouse monoclonal anti-FLAG antibody (Sigma) and an IR Dye 800CW labeled Goat anti-mouse IgG (LI-COR) as a secondary antibody. Immunoprecipitation, metabolic labeling, and pulse chase studies were performed as described in ref.[@R1].

Assays for determining the dominant negative function of specific SIAE variants {#S4}
-------------------------------------------------------------------------------

These assays were carried out by co-transfecting cDNAs encoding V5-tagged wild type murine Siae, together with FLAG-tagged murine versions of *SIAE* mutants discovered in subjects with rheumatoid arthritis into 293T cells. The V5-tagged wild type proteins in cell lysates were immunoprecipitated using mouse monoclonal anti-V5 antibody (Invitrogen), for quantitative immunoblot and esterase activity assays. Expression of FLAG-tagged mutants was also monitored by immunoprecipitation and Western blot assays.

Analysis of Cell surface 9-*O*-acetylation of sialic acid on human B lymphocytes {#S5}
--------------------------------------------------------------------------------

The method used was described in murine lymphocytes in reference1and is based on the method described originally by Krishna and Varki[@R16]. Briefly human B cells were stained with antibodies to CD19 and CD27 (BD Pharmingen) and incubated either with or without F(ab')~2~, polyclonal rabbit anti-human IgM (Dako). Cells were also stained either with FITC-F(ab')~2~, goat anti-human IgG, Fcγ specific (Jackson Immunoresearch) alone, or the CHE-FcD reagent (an Influenza C hemagglutin esterase-fused to the Fc portion of human IgG, chemically treated with diisopropyl fluorophosphate) complexed with FITC-F(ab')~2~ fragment goat anti-human IgG, Fcγ specific. Cells were analyzed by flow cytometry.
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![Analysis of *SIAE* variants from subjects with autoimmunity\
Each *SIAE* variant found in subjects with autoimmunity was re-created by site-directed mutagenesis in a human *SIAE* cDNA, that was then sequenced along its entire length. Wild type (WT) *SIAE*, a known catalytic site mutant (*S127A SIAE*[@R12]), and each *SIAE* variant that was unique to autoimmune subjects were transfected into 293T cells. Assays were performed for *A3G SIAE, N33S SIAE, C196F SIAE, G2121R SIAE, C266G SIAE, Q309P SIAE, T312M SIAE, Y349C SIAE, K400N SIAE, F404S SIAE*, and *R479C SIAE*. Quantitative western blot analysis (using anti-FLAG antibodies) was performed on both the cell lysate and the culture supernatant, and a ratio of these two measurements is shown in the right hand panels of the figure. "Mock" refers to cells which were not transfected but from which lysate and supernatant were analyzed.\
Half of each lysate was immunoprecipitated with anti-FLAG antibodies and examined for esterase activity, presented following normalization for lysate SIAE protein content. Each row shows results from one representative transfection. Each variant was tested in this manner on at least three or more occasions to ensure reproducibility.](nihms199054f1){#F1}

![Analysis of *SIAE* variants from controls\
Each variant identified in control subjects was recreated in an *SIAE* cDNA as described above for subjects with autoimmunity. Wild type (WT) *SIAE*, *S127A SIAE* and each *SIAE* variant that was unique to controls (*R62H SIAE, G64S SIAE, Q161K SIAE, R314H SIAE, H447R SIAE, M456I SIAE*, and *Q462R SIAE*) was transfected into 293T cells. Also shown are results from *M89V SIAE*, which was found in heterozygous form in both patients and controls and in homozygous form only in patients. *T312M SIAE* was observed in one control and in two patients. Results for this variant are included in [Fig. 1](#F1){ref-type="fig"}. Analyses were performed as described in the legend for [Fig. 1](#F1){ref-type="fig"}.](nihms199054f2){#F2}

![Analysis of SIAE mutants in terms of secretion, in vitro dominant interfering activity, and effect on induced cell surface 9-O-acetylation of sialic acid\
a. Murine C196F Siae, and the murine equivalents of Q309P SIAE and T312M SIAE, (Q335P and T338M Siae), function in a dominant interfering fashion but M89V Siae does not. V5-tagged wild type Siae was transfected along with FLAG-tagged C196F Siae or FLAG-tagged M89V Siae and the enzyme activity of V5-tagged wild type Siae was assessed in transfectants as a function of its protein level. Expression of mutant Siae was monitored by an anti-FLAG Western blot of immunoprecipitated mutant proteins (see [Supplementary Fig. 4](#SD1){ref-type="supplementary-material"}).\
b. Pulse-chase analysis comparing secretion of wild type SIAE and M89V SIAE. Transfected 293T cells were metabolically pulse-labeled with ^35^\[S\] methionine and lysates and supernatants were immunoprecipitated with anti-FLAG antibodies after 10 minutes, 1 hour, 2 hours and 4 hours of chase. Proteins were separated by SDS-PAGE and revealed by autofluorography. The position of molecular weight markers is indicated on the left in kilodaltons.\
c. Enhanced 9-*O*-acetylation of sialic acid following BCR ligation in B cells from a subject with a defective *SIAE* mutation. Naïve (CD19^+^CD27^−^) B cells from the peripheral blood of a subject with Crohn's disease (labeled IBD) with a heterozygous *SIAE* mutation (G212R) and from a control subject were analyzed for cell surface 9-*O*-acetylation with and without anti-IgM induced BCR ligation. Cell surface 9-*O*-acetylation was detected using CHE-FcD staining approach as described in Methods. The black tracing reflects CHE-FcD staining and the red represents staining with the second antibody alone.](nihms199054f3){#F3}

###### 

*SIAE* variants identified in Caucasian autoimmune subjects and controls

  ------------------------------------------------------------------------------------------------------
  SIAE Change                               Esterase\      Secretion      Dom. Neg.   Disease   Source
                                            Activity                                            
  ----------------------------------------- -------------- -------------- ----------- --------- --------
  **Autoimmune Patients (n=923)**                                                               

  T312M                                     Defective      Defective      Yes         RA        MGH

  T312M                                     Defective      Defective      Yes         MS        BWH

  Q309P                                     Defective      Defective      Yes         RA        NARAC

  C196F                                     Defective      Defective      Yes         RA        NARAC

  C196F                                     Defective      Defective      Yes         SjS       MGH

  M89V/M89V                                 Normal         Defective      No          RA        NARAC

  M89V/M89V                                 Normal         Defective      No          RA        NARAC

  M89V/M89V                                 Normal         Defective      No          RA        NARAC

  M89V/M89V                                 Normal         Defective      No          SLE       MADGC

  M89V/M89V                                 Normal         Defective      No          MS        BWH

  M89V/M89V                                 Normal         Defective      No          T1D       NIH

  M89V/M89V                                 Normal         Defective      No          T1D       NIH

  M89V/M89V                                 Normal         Defective      No          T1D       NIH

  G212R                                     Defective      Defective      Yes         CD        MGH

  F404S                                     Defective      Defective      Yes         JIA       MADGC

  F404S                                     Defective      Defective      Yes         SLE       MADGC

  F404S                                     Defective      Defective      Yes         UC        MGH

  F404S                                     Defective      Defective      Yes         MS        BWH

  Y349C                                     Defective      Reduced        Yes         SLE       MADGC

  R479C                                     Defective      Defective      Yes         CD        MGH

  W48X                                      Truncated/NT   Truncated/NT   NT          T1D       NIH

  C266G                                     Defective      Defective      NT          T1D       NIH

  R230W                                     Defective      Defective      NT          T1D       NIH

  R393H                                     Defective      Defective      NT          SLE       MGH

                                                                                                

  K400N                                     Normal         Doublet        No          CD        MGH

  A3G                                       Normal         Normal         NT          CD        MGH

  N33S                                      Normal         Normal         NT          RA        NARAC

                                                                                                

  **Ethnically Matched Controls (n=648)**                                                       

                                                                                                

  R314H                                     Defective      Defective      NT          Control   NS/LIJ

  T312M                                     Defective      Defective      Yes         Control   NS/LIJ

                                                                                                

  Q161K                                     Normal         Normal         NT          Control   MGH

  G64S                                      Normal         Normal         NT          Control   MGH

  G64S                                      Normal         Normal         NT          Control   MGH

  G64S                                      Normal         Normal         NT          Control   MGH

  G64S                                      Normal         Normal         NT          Control   MGH

  G64S                                      Normal         Normal         NT          Control   MGH

  G64S                                      Normal         Normal         NT          Control   NS/LIJ

  G64S                                      Normal         Normal         NT          Control   BWH

  G64S                                      Normal         Normal         NT          Control   BWH

  G64S                                      Normal         Normal         NT          Control   BWH

  G64S                                      Normal         Normal         NT          Control   BWH

  Q462R                                     Normal         Normal         NT          Control   MGH

  H447R                                     Normal         Normal         NT          Control   MGH

  R62H                                      Normal         Normal         NT          Control   NS/LIJ

  M456I                                     Normal         Normal         NT          Control   NS/LIJ
  ------------------------------------------------------------------------------------------------------

**Abbreviations**: RA, rheumatoid arthritis; MS, multiple sclerosis; SLE, systemic lupus erythematosus; SjS, Sjogren's syndrome; JIA, juvenile idiopathic arthritis; T1D, Type1 diabetes; CD, Crohn's disease; UC, ulcerative colitis; MGH, Massachusetts General Hospital; BWH, Brigham and Womens' Hospital; NS/LIJ, North Shore Long Island Jewish; NIH, National Institutes of Health; NARAC, North American Rheumatoid Arthritis Consortium; MADGC, Multiple Autoimmune Disorders Genetics Consortium; NT, not tested.

###### 

Functionally defective SIAE coding variants in rheumatoid arthritis, Type I diabetes and all autoimmune diseases combined compared with controls[\*](#TFN2){ref-type="table-fn"}

  ----------------------------------------------------------------------------------------------------------------------------------------
  Disease group          \# of subjects   Odds Ratio (95%\                        Two-tailed p-value[\*\*\*](#TFN4){ref-type="table-fn"}
                                          CI[\*\*](#TFN3){ref-type="table-fn"})   
  ---------------------- ---------------- --------------------------------------- --------------------------------------------------------
  Rheumatoid Arthritis   234              8.31 (1.69 --40.87                      0.0056

  Type I diabetes        252              7.89 (1.58 -- 39.30)                    0.0075

  All Autoimmune\        923              8.62 (2.03 -- 36.62)                    0.0002
  Disorders                                                                       
  ----------------------------------------------------------------------------------------------------------------------------------------

Patients and controls (n=648) were of European ancestry; Jewish subjects were not included in these analyses.

95% CI= 95% Confidence Interval

2 tailed p-value was determined using Fisher's exact test
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